 This meta-analysis compares the efficacy of SBRT and surgery in treating early-stage non-small cell lung cancer, NSCLC, using propensity score matching to achieve comparable treatment hazard ratios for overall survival, local control survival, regional control survival, local regional control survival, distant control survival, disease-free survival, and progression-free survival. The results show that SBRT has similar LC, LRC, DC, DFS, and PFS rates as surgery, but patients with surgery have superior overall survival. However, these conclusions require further studies incorporating comorbidity data and outcomes from randomized control studies to establish the optimal treatment for early-stage NSCLC. This article was authored by Shuang Wen, Li Han, Hu Yi, Li Lv, and others.